Novo Nordisk and Eli Lilly rival soars 30% after promising weight-loss drug results
Zealand Pharma’s Phase 2 trial was an “uniquivocal win” for a drug that can treat both liver disease and obesity, analysts said.
Zealand Pharma’s Phase 2 trial was an “uniquivocal win” for a drug that can treat both liver disease and obesity, analysts said.
